Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PERRIGO Co plcPRGO · Entity 4516 | Director | May 13, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PERRIGO Co plc
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 34,435 |
Ending reported balance
After 2026-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-14 · Exercise / conversion · Acquired 7,305 · Balance 37,942 Row 2 · 2026-05-14 · Tax withholding · Disposed 3,507 · Balance 34,435 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,681 |
Reported balance
After 2026-05-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-13 · Grant · Acquired 16,681 · Balance 16,681 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on May 13 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-14 · Exercise / conversion · Disposed 7,305 · Balance 0 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026. |
| Ordinary SharesSEC Table I · non-derivative | Indirectby Approved Retirement Fund | 1,198 |
Reported balance
Holding disclosure · report date 2026-05-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,198 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.
F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on May 13 2027.
F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theravance Biopharma, Inc.
Report date September 23, 2026 · Filed September 25, 2026
Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-23 · Disposition to issuer · Disposed 74,204 · Balance 6,009 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 6,009 · Balance 0 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2028-04-30 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2029-04-29 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2030-04-27 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.15 · Expires 2032-04-25 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-23 · Disposition to issuer · Disposed 28,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2033-05-01 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-23 · Disposition to issuer · Disposed 22,044 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2034-05-07 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-23 · Disposition to issuer · Disposed 23,576 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2035-05-18 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-23 · Disposition to issuer · Disposed 24,258 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2036-06-11 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-23 · Disposition to issuer · Disposed 13,398 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 13,398 | Not disclosed Strike: $16.64 | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · derivative · entry 11 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,398 shares Expires 2036-06-11 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 24,258 | Not disclosed Strike: $9.39 | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · derivative · entry 10 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 24,258 shares Expires 2035-05-18 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 23,576 | Not disclosed Strike: $9.49 | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · derivative · entry 9 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 23,576 shares Expires 2034-05-07 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 22,044 | Not disclosed Strike: $10.95 | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · derivative · entry 8 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,044 shares Expires 2033-05-01 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 28,000 | Not disclosed Strike: $10.15 | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · derivative · entry 7 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 28,000 shares Expires 2032-04-25 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $20.35 | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · derivative · entry 6 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,000 shares Expires 2031-04-26 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $30.14 | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · derivative · entry 5 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,000 shares Expires 2030-04-27 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $23.85 | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,000 shares Expires 2029-04-29 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $24.43 | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · derivative · entry 3 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,000 shares Expires 2028-04-30 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 6,009 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 74,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001625377-26-000007 · form4-09252026_120902.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,009 F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Read SEC document |
| June 12, 2026 Filed Jun 17, 2026 01:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 13,398 | $0.00 Strike: $16.64 | $0.00 |
DisclosureSEC source: 0001625377-26-000004 · form4-06172026_010644.xml · derivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,398 Underlying: Ordinary Shares · 13,398 shares Expires 2036-06-11 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| June 12, 2026 Filed Jun 17, 2026 01:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001625377-26-000004 · form4-06172026_010644.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,213 Read SEC document |
| May 14, 2026 Filed May 15, 2026 17:15 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 7,305 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001625377-26-000002 · wk-form4_1778865321.xml · derivative · entry 5 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,305 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026. Read SEC document |
| May 14, 2026 Filed May 15, 2026 17:15 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 3,507 | $10.84 | $38,015.88 |
DisclosureSEC source: 0001625377-26-000002 · wk-form4_1778865321.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,435 Read SEC document |
| May 14, 2026 Filed May 15, 2026 17:15 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 7,305 | $10.84 | $79,186.20 |
DisclosureSEC source: 0001625377-26-000002 · wk-form4_1778865321.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2026 Filed May 15, 2026 17:15 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 16,681 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001625377-26-000002 · wk-form4_1778865321.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,681 Underlying: Ordinary Shares · 16,681 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on May 13 2027. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on May 13 2027. Read SEC document |
| May 19, 2025 Filed May 21, 2025 23:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 24,258 | $0.00 Strike: $9.39 | $0.00 |
DisclosureSEC source: 0001415889-25-014017 · form4-05212025_110551.xml · derivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,258 Underlying: Ordinary Shares · 24,258 shares Expires 2035-05-18 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 19, 2025 Filed May 21, 2025 23:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 10,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014017 · form4-05212025_110551.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,204 Read SEC document |
| May 14, 2025 Filed May 16, 2025 15:52 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 9,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-25-000075 · wk-form4_1747410758.xml · derivative · entry 5 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. Read SEC document |
| May 14, 2025 Filed May 16, 2025 15:52 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 7,305 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-25-000075 · wk-form4_1747410758.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,305 Underlying: Ordinary Shares · 7,305 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026. Read SEC document |
| May 14, 2025 Filed May 16, 2025 15:52 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 4,754 | $26.01 | $123,651.54 |
DisclosureSEC source: 0001585364-25-000075 · wk-form4_1747410758.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,637 Read SEC document |
| May 14, 2025 Filed May 16, 2025 15:52 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 9,904 | $26.01 | $257,603.04 |
DisclosureSEC source: 0001585364-25-000075 · wk-form4_1747410758.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 16, 2024 23:28 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 8,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-24-000089 · wk-form4_1715902083.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 23:28 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 4,207 | $30.22 | $127,135.54 |
DisclosureSEC source: 0001585364-24-000089 · wk-form4_1715902083.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,487 Read SEC document |
| May 15, 2024 Filed May 16, 2024 23:28 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 8,764 | $30.22 | $264,848.08 |
DisclosureSEC source: 0001585364-24-000089 · wk-form4_1715902083.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:28 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 9,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-24-000089 · wk-form4_1715902083.xml · derivative · entry 3 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,904 Underlying: Ordinary Shares · 9,904 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. Read SEC document |
| May 08, 2024 Filed May 10, 2024 22:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 23,576 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001415889-24-012917 · form4-05102024_100546.xml · derivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,576 Underlying: Ordinary Shares · 23,576 shares Expires 2034-05-07 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 08, 2024 Filed May 10, 2024 22:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 10,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012917 · form4-05102024_100546.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,555 Read SEC document |
| May 17, 2023 Filed May 19, 2023 18:38 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 7,778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-23-000097 · wf-form4_168452151725680.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2022. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. Read SEC document |
| May 17, 2023 Filed May 19, 2023 18:38 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 3,734 | $32.86 | $122,699.24 |
DisclosureSEC source: 0001585364-23-000097 · wf-form4_168452151725680.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,930 Read SEC document |
| May 17, 2023 Filed May 19, 2023 18:38 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 7,778 | $32.86 | $255,585.08 |
DisclosureSEC source: 0001585364-23-000097 · wf-form4_168452151725680.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2022. Read SEC document |
| May 15, 2023 Filed May 18, 2023 00:14 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 8,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-23-000084 · wf-form4_168436883085217.xml · derivative · entry 3 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,764 Underlying: Ordinary Shares · 8,764 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 22,044 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001415889-23-007382 · form4-05042023_100535.xml · derivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,044 Underlying: Ordinary Shares · 22,044 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007382 · form4-05042023_100535.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,018 Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 23:57 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 10,000 | $10.50 | $105,000.00 |
DisclosureSEC source: 0001415889-22-011763 · form4-11232022_111144.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,886 F1 · shares: Represents ordinary shares tendered by the reporting person and accepted for payment and purchased by the issuer in the issuer's Dutch auction tender offer for up to $95 million of its ordinary shares. Read SEC document |
| May 17, 2022 Filed May 19, 2022 17:54 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 6,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-22-000057 · wf-form4_165298284498196.xml · derivative · entry 5 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2021. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2022. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2022. Read SEC document |
| May 17, 2022 Filed May 19, 2022 17:54 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 7,778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-22-000057 · wf-form4_165298284498196.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,778 Underlying: Ordinary Shares · 7,778 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. Read SEC document |
| May 17, 2022 Filed May 19, 2022 17:54 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 3,168 | $38.57 | $122,189.76 |
DisclosureSEC source: 0001585364-22-000057 · wf-form4_165298284498196.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,886 Read SEC document |
| May 17, 2022 Filed May 19, 2022 17:54 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 6,599 | $38.57 | $254,523.43 |
DisclosureSEC source: 0001585364-22-000057 · wf-form4_165298284498196.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2021. Read SEC document |
| April 26, 2022 Filed Apr 29, 2022 01:18 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $10.15 | $0.00 |
DisclosureSEC source: 0001415889-22-004334 · form4-04282022_060449.xml · derivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Ordinary Shares · 28,000 shares Expires 2032-04-25 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 26, 2022 Filed Apr 29, 2022 01:18 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004334 · form4-04282022_060449.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,886 Read SEC document |
| May 17, 2021 Filed May 19, 2021 16:59 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 6,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-21-000086 · wf-form4_162144357140600.xml · derivative · entry 3 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,599 Underlying: Ordinary Shares · 6,599 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 3 equal annual installments beginning 17 May 2022. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 3 equal annual installments beginning 17 May 2022. Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:56 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 5,804 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-21-000058 · wf-form4_162075937511440.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,804 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on 7 May 2020. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:56 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 2,786 | $42.96 | $119,686.56 |
DisclosureSEC source: 0001585364-21-000058 · wf-form4_162075937511440.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,455 Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:56 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 5,804 | $42.96 | $249,339.84 |
DisclosureSEC source: 0001585364-21-000058 · wf-form4_162075937511440.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 7 May 2020. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $20.35 | $0.00 |
DisclosureSEC source: 0001179110-21-004702 · edgar.xml · derivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004702 · edgar.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,034 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:41 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 6,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-20-000065 · wf-form4_158993525971538.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,054 shares Expires 2020-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2019. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:41 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 2,906 | $52.76 | $153,320.56 |
DisclosureSEC source: 0001585364-20-000065 · wf-form4_158993525971538.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,437 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.